{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:32:04Z","timestamp":1773189124387,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"vor","delay-in-days":364,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2018]]},"DOI":"10.6061\/clinics\/2018\/e476s","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T09:51:58Z","timestamp":1539683518000},"page":"e476s","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S1","title":["Improving adenoviral vectors and strategies for prostate cancer gene therapy"],"prefix":"10.1016","volume":"73","author":[{"given":"Rodrigo Esaki","family":"Tamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor Vieira","family":"de Luna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlous Gomes","family":"Lana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan E","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib1","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.6061\/clinics\/2018\/e476s_bib2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.6061\/clinics\/2018\/e476s_bib3","first-page":"187","article-title":"Is there an optimal management for localized prostate cancer?","volume":"5","author":"Singh","year":"2010","journal-title":"Clin Interv Aging"},{"issue":"4","key":"10.6061\/clinics\/2018\/e476s_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2174\/1389450111314040007","article-title":"The role of tumor suppressor dysregulation in prostate cancer progression","volume":"14","author":"Dean","year":"2013","journal-title":"Curr Drug Targets"},{"issue":"5","key":"10.6061\/clinics\/2018\/e476s_bib5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.urolonc.2005.09.003","article-title":"Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE","volume":"24","author":"Ryan","year":"2006","journal-title":"Urol Oncol"},{"issue":"15","key":"10.6061\/clinics\/2018\/e476s_bib6","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJMp048178","article-title":"Mechanisms of androgen-refractory prostate cancer","volume":"351","author":"Debes","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.6061\/clinics\/2018\/e476s_bib7","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Transl Androl Urol"},{"issue":"15","key":"10.6061\/clinics\/2018\/e476s_bib8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.6061\/clinics\/2018\/e476s_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrurol.2014.36","article-title":"Prostate cancer: treatment sequencing for CRPC-what do we know?","volume":"11","author":"Heidenreich","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"9747","key":"10.6061\/clinics\/2018\/e476s_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"3 Suppl 1","key":"10.6061\/clinics\/2018\/e476s_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/suro.2002.35051","article-title":"Hormonal therapy of prostate cancer","volume":"20","author":"Debruyne","year":"2002","journal-title":"Semin Urol Oncol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e476s_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1006\/mthe.2002.0682","article-title":"Novel prostate-specific promoter derived from PSA and PSMA enhancers","volume":"6","author":"Lee","year":"2002","journal-title":"Mol Ther"},{"issue":"18","key":"10.6061\/clinics\/2018\/e476s_bib13","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/sj.gt.3301549","article-title":"Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors","volume":"8","author":"Wu","year":"2001","journal-title":"Gene Ther"},{"issue":"8","key":"10.6061\/clinics\/2018\/e476s_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/pros.20560","article-title":"A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors","volume":"67","author":"Kraaij","year":"2007","journal-title":"Prostate"},{"issue":"2","key":"10.6061\/clinics\/2018\/e476s_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/10430340252769743","article-title":"Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters\/enhancers in helper dependente compared with first-generation adenoviral vectors","volume":"13","author":"Shi","year":"2002","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.6061\/clinics\/2018\/e476s_bib16","first-page":"334","article-title":"Prostate-specific antigen promoter\/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector","volume":"60","author":"Latham","year":"2000","journal-title":"Cancer Res"},{"key":"10.6061\/clinics\/2018\/e476s_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/624632","article-title":"Comparison of prostate-specific promoters and the use of PSP-driven virotherapy for prostate cancer","volume":"2013","author":"Lu","year":"2013","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1078-0432.CCR-07-0867","article-title":"Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy","volume":"14","author":"Li","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib19","first-page":"34","article-title":"Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5\/3-CTV)","volume":"229","author":"Azab","year":"2014","journal-title":"J Cell Physiol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147173","article-title":"Arg-Gly-Asp (RGD)-Modified E1A\/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice","volume":"11","author":"Shen","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.6061\/clinics\/2018\/e476s_bib21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1089\/hum.2016.139","article-title":"Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector","volume":"28","author":"Tamura","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"8","key":"10.6061\/clinics\/2018\/e476s_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/aps.2016.59","article-title":"Dendritic cells serve as a \u201cTrojan horse\u201d for oncolytic adenovirus delivery in the treatment of mouse prostate cancer","volume":"37","author":"Li","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"10.6061\/clinics\/2018\/e476s_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.21","article-title":"Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers","volume":"3","author":"Nguyen","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/147323001204000132","article-title":"Mesenchymal stem cells modified to express interferon-\u03b2 inhibit the growth of prostate cancer in a mouse model","volume":"40","author":"Wang","year":"2012","journal-title":"J Int Med Res"},{"issue":"20","key":"10.6061\/clinics\/2018\/e476s_bib25","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","article-title":"A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer","volume":"14","author":"Small","year":"2006","journal-title":"Mol Ther"},{"issue":"2","key":"10.6061\/clinics\/2018\/e476s_bib27","first-page":"517","article-title":"Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel","volume":"61","author":"Yu","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.cgt.7700881","article-title":"An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer","volume":"13","author":"Cheng","year":"2006","journal-title":"Cancer Gene Ther"},{"issue":"23","key":"10.6061\/clinics\/2018\/e476s_bib29","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-09-1910","article-title":"Phase I clinical trial of na adenovirus\/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results","volume":"15","author":"Lubaroff","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1-3","key":"10.6061\/clinics\/2018\/e476s_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12026-014-8531-2","article-title":"Vaccine immunotherapy for prostate cancer: from mice to men","volume":"59","author":"Lubaroff","year":"2014","journal-title":"Immunol Res"},{"issue":"18 Pt 1","key":"10.6061\/clinics\/2018\/e476s_bib31","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1158\/1078-0432.CCR-07-0342","article-title":"Faz ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.6061\/clinics\/2018\/e476s_bib32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/cts.12362","article-title":"Feasibility of Neoadjuvant Ad-REIC Gene Therapy in Patients with High-Risk Localized Prostate Cancer Undergoing Radical Prostatectomy","volume":"8","author":"Kumon","year":"2015","journal-title":"Clin Transl Sci"},{"issue":"22","key":"10.6061\/clinics\/2018\/e476s_bib33","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-11-1899","article-title":"GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy","volume":"17","author":"Sonpavde","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.6061\/clinics\/2018\/e476s_bib34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/gt.2014.46","article-title":"Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer","volume":"21","author":"Yang","year":"2014","journal-title":"Gene Ther"},{"issue":"17","key":"10.6061\/clinics\/2018\/e476s_bib35","first-page":"4968","article-title":"Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer","volume":"62","author":"Freytag","year":"2002","journal-title":"Cancer Res"},{"issue":"21","key":"10.6061\/clinics\/2018\/e476s_bib36","first-page":"7497","article-title":"Phase I study of replication competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer","volume":"63","author":"Freytag","year":"2003","journal-title":"Cancer Res"},{"issue":"4","key":"10.6061\/clinics\/2018\/e476s_bib37","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/sj.mt.6300096","article-title":"Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy","volume":"15","author":"Nasu","year":"2007","journal-title":"Mol Ther"},{"issue":"7","key":"10.6061\/clinics\/2018\/e476s_bib38","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/10430349950018229","article-title":"In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial","volume":"10","author":"Herman","year":"1999","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.6061\/clinics\/2018\/e476s_bib39","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1089\/hum.2007.074","article-title":"Long-term outcome of phase I\/II clinical trial of Ad-OC-TK\/VAL gene therapy for hormone-refractory metastatic prostate cancer","volume":"18","author":"Shirakawa","year":"2007","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.6061\/clinics\/2018\/e476s_bib40","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.mt.6300068","article-title":"Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol Ther"},{"issue":"5","key":"10.6061\/clinics\/2018\/e476s_bib41","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/mt.sj.6300120","article-title":"Phase I trial of replication competente adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol Ther"},{"issue":"11","key":"10.6061\/clinics\/2018\/e476s_bib42","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/cgt.2013.56","article-title":"Intraprostatic distribution and long term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer","volume":"20","author":"Rojas-Mart\u00ednez","year":"2013","journal-title":"Cancer Gene Ther"},{"issue":"5393","key":"10.6061\/clinics\/2018\/e476s_bib43","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.282.5393.1497","article-title":"Requirement for p53 and p21 to sustain G2 arrest after DNA damage","volume":"282","author":"Bunz","year":"1998","journal-title":"Science"},{"issue":"3","key":"10.6061\/clinics\/2018\/e476s_bib44","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","article-title":"PUMA, a novel proapoptotic gene, is induced by p53","volume":"7","author":"Nakano","year":"2000","journal-title":"Mol Cell"},{"issue":"16","key":"10.6061\/clinics\/2018\/e476s_bib45","first-page":"3814","article-title":"An uncertain role for p53 gene alterations in human prostate cancers","volume":"56","author":"Brooks","year":"1996","journal-title":"Cancer Res"},{"issue":"Database issue","key":"10.6061\/clinics\/2018\/e476s_bib46","doi-asserted-by":"crossref","first-page":"D962","DOI":"10.1093\/nar\/gks1033","article-title":"The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis","volume":"41","author":"Leroy","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.6061\/clinics\/2018\/e476s_bib47","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/ijc.28784","article-title":"Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer","volume":"135","author":"Kluth","year":"2014","journal-title":"Int J Cancer"},{"issue":"7","key":"10.6061\/clinics\/2018\/e476s_bib48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/gcc.20560","article-title":"Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate","volume":"47","author":"Bettendorf","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"10.6061\/clinics\/2018\/e476s_bib49","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/modpathol.2008.145","article-title":"KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations","volume":"21","author":"Agell","year":"2008","journal-title":"Mod Pathol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1399-0004.2005.00452.x","article-title":"Chromosomal changes in prostate cancer: a fluorescence in situ hybridization study","volume":"68","author":"Das","year":"2005","journal-title":"Clin Genet"},{"issue":"9","key":"10.6061\/clinics\/2018\/e476s_bib51","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm0996-985","article-title":"Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer","volume":"2","author":"Roth","year":"1996","journal-title":"Nat Med"},{"issue":"9","key":"10.6061\/clinics\/2018\/e476s_bib52","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001222","article-title":"p53-based cancer therapy","volume":"2","author":"Lane","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib53","first-page":"5","article-title":"High efficiency gene transfer and high-level expression of wild-type p53 in human lung c\u00e2ncer cells mediated by recombinant adenovirus","volume":"1","author":"Zhang","year":"1994","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.6061\/clinics\/2018\/e476s_bib54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2165\/00063030-200317030-00010","article-title":"INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy\u2013Introgen, RPR\/INGN 201","volume":"17","year":"2003","journal-title":"BioDrugs"},{"issue":"9","key":"10.6061\/clinics\/2018\/e476s_bib55","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1089\/hum.1994.5.9-1079","article-title":"Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer","volume":"5","author":"Wills","year":"1994","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.6061\/clinics\/2018\/e476s_bib56","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1200\/JCO.2001.19.6.1750","article-title":"Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study","volume":"19","author":"Schuler","year":"2001","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.6061\/clinics\/2018\/e476s_bib57","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1089\/hum.1998.9.14-2075","article-title":"A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer","volume":"9","author":"Schuler","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.6061\/clinics\/2018\/e476s_bib58","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.cgt.7700473","article-title":"Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500","volume":"9","author":"Buller","year":"2002","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"10.6061\/clinics\/2018\/e476s_bib59","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.cgt.7700472","article-title":"A phase I\/II trial of rAd\/p53 (SCH 58500) gene replacement in recurrent ovarian cancer","volume":"9","author":"Buller","year":"2002","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"10.6061\/clinics\/2018\/e476s_bib60","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1200\/JCO.2002.20.4.957","article-title":"Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation","volume":"20","author":"Kuball","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e476s_bib61","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.cgt.7700870","article-title":"Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial","volume":"13","author":"Atencio","year":"2006","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"10.6061\/clinics\/2018\/e476s_bib62","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1089\/hum.2005.16.1016","article-title":"Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers","volume":"16","author":"Peng","year":"2005","journal-title":"Hum Gene Ther"},{"issue":"25","key":"10.6061\/clinics\/2018\/e476s_bib63","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1056\/NEJMoa073770","article-title":"TP53 mutations and survival in squamous-cell carcinoma of the head and neck","volume":"357","author":"Poeta","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.6061\/clinics\/2018\/e476s_bib64","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1158\/1078-0432.CCR-03-0388","article-title":"Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer","volume":"10","author":"Pisters","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.6061\/clinics\/2018\/e476s_bib65","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1089\/hum.1996.7.14-1683","article-title":"Molecular therapy with recombinant p53 adenovirus in na androgen-independent, metastatic human prostate cancer model","volume":"7","author":"Ko","year":"1996","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.6061\/clinics\/2018\/e476s_bib66","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<377::AID-IJC13>3.0.CO;2-D","article-title":"Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector","volume":"71","author":"Asgari","year":"1997","journal-title":"Int J Cancer"},{"issue":"19","key":"10.6061\/clinics\/2018\/e476s_bib67","first-page":"4210","article-title":"Adenovirus-mediated wild type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells","volume":"55","author":"Yang","year":"1995","journal-title":"Cancer Res"},{"issue":"22","key":"10.6061\/clinics\/2018\/e476s_bib68","first-page":"5151","article-title":"In vivo gene therapy with p53 or p21 adenovirus for prostate cancer","volume":"55","author":"Eastham","year":"1995","journal-title":"Cancer Res"},{"issue":"2","key":"10.6061\/clinics\/2018\/e476s_bib69","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2003.12.021","article-title":"pCLPG: a p53-driven retroviral system","volume":"321","author":"Strauss","year":"2004","journal-title":"Virology"},{"issue":"12","key":"10.6061\/clinics\/2018\/e476s_bib70","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.cgt.7700846","article-title":"A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition","volume":"12","author":"Strauss","year":"2005","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.virol.2007.11.015","article-title":"Development of an adenoviral vector with robust expression driven by p53","volume":"371","author":"Bajgelman","year":"2008","journal-title":"Virology"},{"issue":"12","key":"10.6061\/clinics\/2018\/e476s_bib72","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/15384047.2016.1235655","article-title":"Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy","volume":"17","author":"Tamura","year":"2016","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"10.6061\/clinics\/2018\/e476s_bib73","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/0970-1591.191239","article-title":"Chemotherapy options in castration-resistant prostate cancer","volume":"32","author":"Teply","year":"2016","journal-title":"Indian J Urol"},{"issue":"24","key":"10.6061\/clinics\/2018\/e476s_bib74","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/0006-2952(85)90275-8","article-title":"Interactions of antitumor agentes Ametantrone and Mitoxantrone (Novatrone) with double-stranded DNA","volume":"34","author":"Kapuscinski","year":"1985","journal-title":"Biochem Pharmacol"},{"issue":"17","key":"10.6061\/clinics\/2018\/e476s_bib75","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1073\/pnas.83.17.6302","article-title":"Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids","volume":"83","author":"Kapuscinski","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.6061\/clinics\/2018\/e476s_bib76","doi-asserted-by":"crossref","first-page":"60","DOI":"10.14712\/fb2015061020060","article-title":"Subcellular Localization of Proteins Responding to Mitoxantrone-Induced DNA Damage in Leukaemic Cells","volume":"61","author":"\u0106 \u0106mielov\u00e1","year":"2015","journal-title":"Folia Biol (Praha)"},{"issue":"5","key":"10.6061\/clinics\/2018\/e476s_bib77","first-page":"1021","article-title":"Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line","volume":"59","author":"Hazlehurst","year":"1999","journal-title":"Cancer Res"},{"issue":"4","key":"10.6061\/clinics\/2018\/e476s_bib78","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1091\/mbc.10.4.947","article-title":"Taxol suppresses dynamics of individual microtubules in living human tumor cells","volume":"10","author":"Yvon","year":"1999","journal-title":"Mol Biol Cell"},{"issue":"9","key":"10.6061\/clinics\/2018\/e476s_bib79","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J Am Chem Soc"},{"issue":"24","key":"10.6061\/clinics\/2018\/e476s_bib80","doi-asserted-by":"crossref","first-page":"8147","DOI":"10.1158\/1078-0432.CCR-04-1402","article-title":"Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer","volume":"10","author":"Dagher","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.6061\/clinics\/2018\/e476s_bib81","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1568011033482422","article-title":"Signal transduction pathways of taxanes-induced apoptosis","volume":"3","author":"Ganansia-Leymarie","year":"2003","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"4","key":"10.6061\/clinics\/2018\/e476s_bib82","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/pros.22583","article-title":"Functional p53 determines docetaxel sensitivity in prostate cancer cells","volume":"73","author":"Liu","year":"2013","journal-title":"Prostate"},{"issue":"24","key":"10.6061\/clinics\/2018\/e476s_bib83","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.4161\/cc.22852","article-title":"p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3","volume":"11","author":"Chappell","year":"2012","journal-title":"Cell Cycle"},{"issue":"6","key":"10.6061\/clinics\/2018\/e476s_bib84","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1758834012449685","article-title":"Overcoming docetaxel resistance in prostate cancer: a perspective review","volume":"4","author":"Hwang","year":"2012","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"10.6061\/clinics\/2018\/e476s_bib85","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/cmdc.200600308","article-title":"Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes","volume":"2","author":"Galletti","year":"2007","journal-title":"ChemMedChem"},{"issue":"6","key":"10.6061\/clinics\/2018\/e476s_bib86","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.juro.2011.02.016","article-title":"Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer","volume":"185","author":"Kosaka","year":"2011","journal-title":"J Urol"},{"key":"10.6061\/clinics\/2018\/e476s_bib87","first-page":"117","article-title":"Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer","volume":"5","author":"Paller","year":"2011","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"10.6061\/clinics\/2018\/e476s_bib88","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1535-7163.MCT-14-0265","article-title":"Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells","volume":"13","author":"Azarenko","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"4617","key":"10.6061\/clinics\/2018\/e476s_bib89","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1126\/science.6137059","article-title":"Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines","volume":"221","author":"Kartner","year":"1983","journal-title":"Science"},{"issue":"2","key":"10.6061\/clinics\/2018\/e476s_bib90","first-page":"64","article-title":"Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies","volume":"3","author":"Armstrong","year":"2015","journal-title":"Am J Clin Exp Urol"},{"key":"10.6061\/clinics\/2018\/e476s_bib91","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6548","article-title":"ERG induces taxane resistance in castration-resistant prostate cancer","volume":"5","author":"Galletti","year":"2014","journal-title":"Nat Commun"},{"key":"10.6061\/clinics\/2018\/e476s_bib92","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/DDDT.S64940","article-title":"Preclinical profile of cabazitaxel","volume":"8","author":"Vrignaud","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"10.6061\/clinics\/2018\/e476s_bib93","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/cgt.2011.15","article-title":"Docetaxel plus trans-tracheal injection of adenoviral-mediated p53 versus docetaxel alone in patients with previously treated non-small-cell lung cancer","volume":"18","author":"Ning","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.6061\/clinics\/2018\/e476s_bib94","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1741-7015-12-16","article-title":"Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial","volume":"12","author":"Li","year":"2014","journal-title":"BMC Med"},{"issue":"5","key":"10.6061\/clinics\/2018\/e476s_bib95","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.3892\/ol.2017.5901","article-title":"Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: a clinical trial","volume":"13","author":"Xiao","year":"2017","journal-title":"Oncol Lett"},{"issue":"6","key":"10.6061\/clinics\/2018\/e476s_bib96","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/147323000803600614","article-title":"Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin","volume":"36","author":"Dong","year":"2008","journal-title":"J Int Med Res"},{"issue":"5","key":"10.6061\/clinics\/2018\/e476s_bib97","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1631\/jzus.B0820248","article-title":"Adenovirus-mediated wild type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up","volume":"10","author":"Guan","year":"2009","journal-title":"J Zhejiang Univ Sci B"},{"issue":"11","key":"10.6061\/clinics\/2018\/e476s_bib98","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2005.03.4116","article-title":"Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer","volume":"24","author":"Fujiwara","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.6061\/clinics\/2018\/e476s_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/srep39355","article-title":"Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion","volume":"6","author":"Biaoxue","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.6061\/clinics\/2018\/e476s_bib100","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/CAD.0b013e32832dad3d","article-title":"Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy","volume":"20","author":"Miettinen","year":"2009","journal-title":"Anticancer Drugs"},{"issue":"9","key":"10.6061\/clinics\/2018\/e476s_bib101","first-page":"2887","article-title":"Synergistic inhibition of human lung cancer cell growth by adenov\u00edrus mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo","volume":"7","author":"Nishizaki","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.6061\/clinics\/2018\/e476s_bib102","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.cgt.7700148","article-title":"Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells","volume":"7","author":"Horio","year":"2000","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib103","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0304-3835(00)00480-8","article-title":"Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene","volume":"157","author":"Inoue","year":"2000","journal-title":"Cancer Lett"},{"issue":"6","key":"10.6061\/clinics\/2018\/e476s_bib104","first-page":"383","article-title":"A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers","volume":"4","author":"Seth","year":"1997","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.6061\/clinics\/2018\/e476s_bib105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.amjoto.2008.10.002","article-title":"Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model","volume":"31","author":"Yoo","year":"2010","journal-title":"Am J Otolaryngol"},{"issue":"11","key":"10.6061\/clinics\/2018\/e476s_bib106","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/01.mlg.0000147914.51239.ed","article-title":"Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer","volume":"114","author":"Yoo","year":"2004","journal-title":"Laryngoscope"},{"issue":"5","key":"10.6061\/clinics\/2018\/e476s_bib107","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/cgt.2008.99","article-title":"Drug v\u00edrus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model","volume":"16","author":"Wonganan","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.6061\/clinics\/2018\/e476s_bib108","first-page":"495","article-title":"Gene therapy approaches to sensitization of human prostate carcinoma to cisplatin by adenoviral expression. of p53 and by antisense jun kinase oligonucleotide methods","volume":"175","author":"Gjerset","year":"2001","journal-title":"Methods Mol Biol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e476s_bib109","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1535-7163.187.4.2","article-title":"Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen independent human prostate cancer model","volume":"4","author":"Yamanaka","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.6061\/clinics\/2018\/e476s_bib110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-5347(05)65465-1","article-title":"Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents","volume":"167","author":"Li","year":"2002","journal-title":"J Urol"},{"issue":"10","key":"10.6061\/clinics\/2018\/e476s_bib111","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1089\/hum.2010.019","article-title":"Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate c\u00e2ncer cells and tumor xenografts","volume":"21","author":"Radhakrishnan","year":"2010","journal-title":"Hum Gene Ther"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:03:55Z","timestamp":1761721435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222011243"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322018000200309&lng=en&nrm=iso&tlng=en","label":"SCIELO"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/improving-adenoviral-vectors-and-strategies-for-prostate-cancer-gene-therapy\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":111,"alternative-id":["S1807593222011243"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e476s","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving adenoviral vectors and strategies for prostate cancer gene therapy","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e476s","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e476s"}}